← Back to all signals
RESEARCH PAPER ANALYSIS

Inflammatory cytokines as biomarkers for disease severity in pediatric viral pneumonia: a systematic review and meta-analysis.

AI interpretation is pending for this paper.

Open original publication →
PMID41810175
JournalTranslational pediatrics
Publication Date2026-02-12
Ingested2026-08-02 12:06 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: Severe progression of viral pneumonia in children is associated with adverse clinical outcomes. Inflammatory cytokines have been proposed as potential biomarkers for both disease presence and severity; however, existing evidence remains inconsistent. This systematic review and meta-analysis aimed to evaluate the association between inflammatory cytokines and pediatric viral pneumonia by comparing healthy controls with affected children, as well as children with mild disease versus those with moderate-to-severe disease, and to further assess the diagnostic performance of interleukin-6 (IL-6). METHODS: A systematic literature search was conducted in seven databases up to January 25, 2026. Studies involving children (<18 years) with viral pneumonia that reported inflammatory cytokine levels in healthy controls and patients, or stratified patients by disease severity, were included. A total of 19 studies were ultimately included in the meta-analysis. Weighted mean differences (WMDs) with 95% confidence intervals (CIs) were pooled using random-effects models. Subgroup, sensitivity, and publication bias analyses were performed. A diagnostic test accuracy meta-analysis was conducted to evaluate the ability of IL-6 to identify moderate-to-severe disease. RESULTS: Nineteen studies were included. Compared with healthy controls, children with viral pneumonia had significantly higher levels of IL-6, C-reactive protein (CRP), procalcitonin (PCT), and tumor necrosis factor-α (TNF-α). Further severity-stratified analysis showed that children in the moderate-to-severe group had significantly higher levels of IL-6 (WMD =-13.07, 95% CI: -16.88 to -9.26), CRP (WMD =-10.16, 95% CI: -17.20 to -3.12), PCT (WMD =-0.37, 95% CI: -0.59 to -0.15), and TNF-α (WMD =-1.08, 95% CI: -1.65 to -0.51) compared with those in the mild group. Subgroup analyses demonstrated that IL-6 consistently discriminated disease severity across pathogen types, age groups, and sample sizes. The pooled sensitivity and specificity of IL-6 for identifying moderate-to-severe disease were 0.80 (95% CI: 0.68-0.89) and 0.78 (95% CI: 0.64-0.87), respectively, with an area under the summary receiver operating characteristic curve of 0.86. CONCLUSIONS: Inflammatory cytokines are significantly elevated in children with viral pneumonia compared with healthy controls and are further increased in those with moderate-to-severe disease. Among these biomarkers, IL-6 demonstrates stable severity discrimination and moderate diagnostic accuracy, suggesting its potential value for early identification of children at risk of severe disease progression.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Biomarker-Negative and MIBG-Negative Neuroblastoma Presenting as an Indeterminate Retroperitoneal Mass in a Young Child. Pediatrics international : official journal of the Japan Pediatric Society 29.85 2 Hypophosphatemic rickets in children: current knowledge and a proposal for a diagnostic algorithm. Endokrynologia Polska 58.0 3 Effectiveness of the "Golden Hour" program in preventing sepsis in pediatric patients with acute lymphoblastic leukemia. Boletin medico del Hospital Infantil de Mexico 65.0 4 Clinical validation of the nursing diagnosis of inadequate nutritional intake in children with cancer. International journal of nursing knowledge 67.6 5 Exploratory Analysis of the Inhibitory Effects of Propranolol on NLRP3 and Pyrin Inflammasomes. ACR open rheumatology 56.76 6 First-In-Human Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of Tilpisertib Fosmecarbil (GS-5290), an Oral Prodrug of a Tumor Progression Locus 2 Inhibitor in Healthy Participants. Journal of clinical pharmacology 84.72 7 Dyadic Latent Profiles of Sexual and Reproductive Distress in Young Adult Cancer Survivors and Their Partners: A Cross-Sectional Analysis. Psycho-oncology 61.0 8 Disproportionality analysis of drug-induced myocarditis: Insights from the Food and Drug Administration Adverse Event Reporting System database. The Journal of international medical research 63.68 9 Innovative Insights into Osteosarcoma: Unraveling the Role of LncRNAs, miRNAs, and CircRNAs in Tumorigenesis and Therapeutic Resistance. Current gene therapy 63.84 10 Targeting Metal-Dependent Cell Death in Cancer: From Molecular Circuitry to Biomarker-Guided Precision Combination Therapy. Current cancer drug targets 70.99 11 Long-term outcomes of non-operative compared to operative management of acute uncomplicated appendicitis - a systematic review and meta-analysis. American journal of surgery 72.5 12 What have I missed again: A qualitative study exploring parents of children with cancer's experiences of fear of missing out. Journal of health psychology 54.0 13 Radiographic overestimation of inferior vena cava involvement in pediatric neuroblastoma: a case report. Journal of surgical case reports 55.5 14 Global Burden and Temporal Trends of Brain and Central Nervous System Tumors in Children and Adolescents: A Systematic Analysis for the Global Burden of Disease Study 2021. Cancer innovation 56.0 15 Refractory Hyperammonemic Encephalopathy as a Paraneoplastic Presentation of Fibrolamellar Hepatocellular Carcinoma: A Case Report. The American journal of case reports 53.92 16 Modern management and multidisciplinary care of bladder prostate rhabdomyosarcoma. Current opinion in pediatrics 62.8 17 Improving Dietary Data Quality in Nutrition Studies: Development and Validation of an Explainable, Reproducible, Open Machine Learning-Assisted Framework for Outlier Detection in 24-Hour Recalls. American journal of epidemiology 61.5 18 Genetic Markers of Early Skeletal Muscle Loss in Adolescent and Young Adult Cancer Patients Treated with Anthracyclines. Journal of adolescent and young adult oncology 65.5 19 Seen, Heard, and Still Missing: Understanding Clinical Trial Nonparticipation Among Women of Color. Journal of adolescent and young adult oncology 74.5 20 Correction to "Health-Related Quality of Life in Chinese Children and Adolescents With Cancer: A Systematic Review and Meta-Analysis". International journal of cancer 63.0 21 Evolution of robotic-assisted resection of pediatric neuroblastic tumors: a retrospective analysis. Updates in surgery 61.5 22 Late cardiac effects of anthracycline-based therapy in childhood cancer survivors: a CMR study of cardiac strain and function. Clinical research in cardiology : official journal of the German Cardiac Society 68.34 23 Biological reconstruction in the growing child after tumour resection: long-term outcomes of vascularized fibular epiphyseal transfer. International orthopaedics 57.2 24 Neuroimaging findings of the hypothalamus and pituitary gland in children with growth hormone deficiency: a 25-year single-center retrospective study. Hormones (Athens, Greece) 67.0 25 Ovarian Lymphoma and Bone Metastasis Presenting With Paraparesis in an Adolescent: A Case Report. The American journal of case reports 51.9 26 Evaluating the impact of virtual oncology financial and legal navigation on cancer-related financial toxicity. JNCI cancer spectrum 63.12 27 Pharmacogenetic variants in the molecular characterization initiative: a report from the children's oncology group. Journal of the National Cancer Institute 65.4 28 Impact of Satisfactory Family Coping on the Mental Health of Parents Whose Children Died of Cancer. Journal of pain and symptom management 59.5 29 Surgical approach to solid breast masses in girls. Journal of pediatric and adolescent gynecology 58.4 30 Pediatric and Adolescent Gynecological Tumors and Associated Predisposition Syndromes. Journal of pediatric and adolescent gynecology 56.0 31 Facial nerve schwannoma of the accessory parotid gland region in a child managed through a transoral approach. BMJ case reports 56.0 32 Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study. The Lancet. Oncology 85.2
PATIENT-FRIENDLY SUMMARY

Inflammatory cytokines as biomarkers for disease severity in pediatric viral pneumonia: a systematic review and meta-analysis.

For education only—not personal medical advice.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic